Stankovich Thomas

Chief Financial OfficerReShape Lifesciences Inc. (RSLS) · full profile →Form 4 · filed Aug 13, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$39
Net Open-Market Flow
-$39
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 31, 2024Sell(S)48$0.25$1223K
Feb 29, 2024Sell(S)43$0.17$723K
Dec 31, 2023Sell(S)42$0.25$1123K
Nov 30, 2023Sell(S)39$0.23$923K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001235802-24-000059) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Ask your agent about RSLS insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001235802-24-000059"
Ask your agent
Use Arkolith to summarize insider buying and selling at ReShape Lifesciences Inc.
over the last 90 days and cite the filings.